Pioglitazone.txt

CLINICAL USE

Treatment of type 2 diabetes mellitus

DOSE IN NORMAL RENAL FUNCTION

15–45 mg daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :392.9 (as hydrochloride)

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>99

%Excreted unchanged in urine &nbsp &nbsp : <1

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.25

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :5–6 (active metabolites: 16–23)/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function and monitor carefully

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in normal renal function and monitor carefully

HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function and monitor carefully

CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function and monitor carefully

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Liver function tests should be measured prior to initiation of therapy and then every 2 months for the first 12 months, and thereafter at regular intervalsPioglitazone should not be used in patients with heart failure or history of heart failure; incidence of heart failure is increased when pioglitazone is combined with insulin. Patients should be closely monitored for signs of heart failure.

Tags: post-by-auto-php